These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 23959305)

  • 1. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly.
    Wu G; Liu B; Zhang Y; Li J; Arzumanyan A; Clayton MM; Schinazi RF; Wang Z; Goldmann S; Ren Q; Zhang F; Feitelson MA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5344-54. PubMed ID: 23959305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.
    Wang XY; Wei ZM; Wu GY; Wang JH; Zhang YJ; Li J; Zhang HH; Xie XW; Wang X; Wang ZH; Wei L; Wang Y; Chen HS
    Antivir Ther; 2012; 17(5):793-803. PubMed ID: 22668794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
    Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379.
    Berke JM; Dehertogh P; Vergauwen K; Mostmans W; Vandyck K; Raboisson P; Pauwels F
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
    Ren Q; Liu X; Luo Z; Li J; Wang C; Goldmann S; Zhang J; Zhang Y
    Bioorg Med Chem; 2017 Feb; 25(3):1042-1056. PubMed ID: 28082068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants.
    Lam AM; Ren S; Espiritu C; Kelly M; Lau V; Zheng L; Hartman GD; Flores OA; Klumpp K
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.
    Cai D; Mills C; Yu W; Yan R; Aldrich CE; Saputelli JR; Mason WS; Xu X; Guo JT; Block TM; Cuconati A; Guo H
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4277-88. PubMed ID: 22644022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein.
    Mani N; Cole AG; Phelps JR; Ardzinski A; Burns R; Chiu T; Cuconati A; Dorsey BD; Evangelista E; Fan K; Guo F; Harasym TO; Kadhim S; Kowalski R; Kultgen SG; Lee ACH; Li AH; Majeski SA; Miller A; Pasetka C; Reid SP; Rijnbrand R; Micolochick Steuer HM; Stever K; Tang S; Teng X; Wang X; Sofia MJ
    Antiviral Res; 2022 Jan; 197():105211. PubMed ID: 34826506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical characterization of a novel potent core protein assembly modulator for the treatment of chronic hepatitis B viral infection.
    Dunkoksung W; Udomnilobol U; Ruengsatra T; Chauypen N; Prueksaritanont T
    Eur J Pharm Sci; 2024 Sep; 200():106834. PubMed ID: 38906232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.
    Schinazi RF; Bassit L; Clayton MM; Sun B; Kohler JJ; Obikhod A; Arzumanyan A; Feitelson MA
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6186-91. PubMed ID: 22985879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective depletion of HBV-infected hepatocytes by class A capsid assembly modulators requires high levels of intrahepatic HBV core protein.
    Kornyeyev D; Song Z; Eng S; Soulette C; Ramirez R; Tang J; Yue Q; Subramanian R; Zaboli S; Moon C; Tam J; Brodbeck J; Aggarwal A; Diehl L; Fletcher SP; Hyrina A; Holdorf MM; Burdette D
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0042024. PubMed ID: 38780261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.
    Wang J; Zhang H; Zhang Y; Jiang D; Li J; Goldmann S; Ren Q; Fei R; Wang X; Wei L
    J Med Virol; 2017 Oct; 89(10):1804-1810. PubMed ID: 28401569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
    Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
    Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.
    Boucle S; Lu X; Bassit L; Ozturk T; Russell OO; Amblard F; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2017 Feb; 27(4):904-910. PubMed ID: 28094179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors.
    Ma Y; Zhao S; Ren Y; Cherukupalli S; Li Q; Woodson ME; Bradley DP; Tavis JE; Liu X; Zhan P
    Eur J Med Chem; 2021 Dec; 225():113780. PubMed ID: 34438123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
    Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
    J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly.
    Kang JA; Kim S; Park M; Park HJ; Kim JH; Park S; Hwang JR; Kim YC; Jun Kim Y; Cho Y; Sun Jin M; Park SG
    Nat Commun; 2019 May; 10(1):2184. PubMed ID: 31097716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors.
    Jia H; Yu J; Du X; Cherukupalli S; Zhan P; Liu X
    Eur J Med Chem; 2020 Sep; 202():112495. PubMed ID: 32712535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells.
    Huber AD; Wolf JJ; Liu D; Gres AT; Tang J; Boschert KN; Puray-Chavez MN; Pineda DL; Laughlin TG; Coonrod EM; Yang Q; Ji J; Kirby KA; Wang Z; Sarafianos SG
    mSphere; 2018 Apr; 3(2):. PubMed ID: 29669885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.